Phase III clinical trial development: A process of chutes and ladders

David M. Dilts, Steven K. Cheng, Joshua S. Crites, Alan B. Sandler, James H. Doroshow

Research output: Contribution to journalComment/debate

48 Scopus citations

Abstract

Purpose: The Institute of Medicine report on cooperative groups and the National Cancer Institute (NCI) report from the Operational Efficiency Working Group both recommend changes to the processes for opening a clinical trial. This article provides evidence for the need for such changes by completing the first comprehensive review of all the time and steps required to open a phase III oncology clinical trial and discusses the effect of time to protocol activation on subject accrual. Methods: The Dilts and Sandler method was used at four cancer centers, two cooperative groups, and the NCI Cancer Therapy Evaluation Program. Accrual data were also collected. Results: Opening a phase III cooperative group therapeutic trial requires 769 steps, 36 approvals, and a median of approximately 2.5 years from formal concept review to study opening. Time to activation at one group ranged from 435 to 1,604 days, and time to open at one cancer center ranged from 21 to 836 days. At centers, group trials are significantly more likely to have zero accruals (38.8%) than non-group trials (20.6%; P < 0.0001). Of the closed NCI Cancer Therapy Evaluation Program-approved phase III clinical trials from 2000 to 2007, 39.1% resulted in <21 accruals. Conclusions: The length, variability, and low accrual results demonstrate the need for the NCI clinical trials system to be reengineered. Improvements will be of only limited effectiveness if done in isolation; there is a need to return to the collaborative spirit with all parties creating an efficient and effective system. Recommendations put forth by the Institute of Medicine and Operational Efficiency Working Group reports, if implemented, will aid this renewal.

Original languageEnglish (US)
Pages (from-to)5381-5389
Number of pages9
JournalClinical Cancer Research
Volume16
Issue number22
DOIs
StatePublished - Nov 15 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase III clinical trial development: A process of chutes and ladders'. Together they form a unique fingerprint.

  • Cite this

    Dilts, D. M., Cheng, S. K., Crites, J. S., Sandler, A. B., & Doroshow, J. H. (2010). Phase III clinical trial development: A process of chutes and ladders. Clinical Cancer Research, 16(22), 5381-5389. https://doi.org/10.1158/1078-0432.CCR-10-1273